Protagenic Therapeutics, Inc.\new Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Protagenic Therapeutics, Inc.\new (PTIX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$944.30 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-19
- Protagenic Therapeutics, Inc.\new cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-06-30 was -$944.30K, a 122.49% decline year-over-year.
- Protagenic Therapeutics, Inc.\new cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-06-30 was $4.20M, a 486.28% increase year-over-year.
- Protagenic Therapeutics, Inc.\new cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-06-30 was $716.19K.
- Protagenic Therapeutics, Inc.\new cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2026 was $1.70M, a 4104.32% increase from fiscal 2025.
- Protagenic Therapeutics, Inc.\new cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $40.36K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$944.30K 10-Q · filed 2026-08-19 | |||
| 2026-03-31 | $1.70M 10-K · filed 2026-08-14 | |||
| 2025-12-31 | $2.28M 10-Q · filed 2026-03-09 | |||
| 2025-09-30 | $2.79M 10-Q · filed 2025-11-26 | |||
| 2025-06-30 | $4.20M 10-Q · filed 2026-08-19 | |||
| 2025-03-31 | $40.36K 10-K · filed 2026-08-14 | |||
| 2024-12-31 | $5.55K 10-Q · filed 2026-03-09 | |||
| 2024-09-30 | $208.97K 10-Q · filed 2025-11-26 | |||
| 2024-06-30 | $716.19K 10-QT · filed 2025-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |